Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Oncology ; 65(3): 211-7, 2003.
Article in English | MEDLINE | ID: mdl-14657594

ABSTRACT

PURPOSE: A phase II trial was performed to determine the antitumor efficacy and tolerance of combined docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer. PATIENTS AND METHODS: Thirty-seven patients with histologically confirmed metastatic gastroesophageal cancer were entered in this trial. Treatment consisted of 4-weekly courses of docetaxel 50 mg/m(2) and cisplatin 50 mg/m(2) both given on day 1 and 15. Depending on absolute neutrophil counts on the days of scheduled chemotherapeutic drug administration (1,000-2,000/microl), a 5-day course of human granulocyte colony-stimulating factor (G-CSF) 5 microg/kg/day was given subcutaneously; in addition, if hemoglobin was <12.0 mg/dl, erythropoietin 10,000 IU was administered subcutaneously 3 times per week. RESULTS: The confirmed overall response rate (intent-to-treat) was 46%, including 4 complete responses (11%) and 13 partial responses (35%). Eleven patients (30%) had stable disease and 9 (24%) progressed while on treatment. The median time to response was 3 months, the median time to progression was 7 months and the median overall survival time was 11.5 months with 16 (43%) patients currently alive. Hematologic toxicity was common, though WHO grade 4 neutropenia occurred only in 3 patients. Nonhematologic adverse reaction were usually mild to moderate; grade 3 toxicities included alopecia in 5 patients (14%), infection in 1 (3%), neutrotoxicity in 2 (5%) and anaphylaxis in 1 patient. CONCLUSION: Our data suggest that the combination of docetaxel and cisplatin with or without G-CSF and/or erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Erythropoietin/administration & dosage , Esophageal Neoplasms/drug therapy , Esophagogastric Junction , Granulocyte Colony-Stimulating Factor/administration & dosage , Stomach Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/administration & dosage , Docetaxel , Drug Therapy, Combination , Esophageal Neoplasms/pathology , Esophageal Neoplasms/secondary , Female , Humans , Male , Maximum Tolerated Dose , Middle Aged , Stomach Neoplasms/pathology , Stomach Neoplasms/secondary , Survival Rate , Taxoids/administration & dosage , Treatment Outcome
2.
J Clin Oncol ; 21(7): 1307-12, 2003 Apr 01.
Article in English | MEDLINE | ID: mdl-12663719

ABSTRACT

PURPOSE: Capecitabine and oxaliplatin, two new agents with potential synergistic activity, have demonstrated promising antitumor efficacy in advanced colorectal cancer (ACC). Preclinical and clinical evidence indicating that dose intensification of the oral fluorouracil prodrug might result in improved therapeutic results led us to the present randomized multicenter phase II study. PATIENTS AND METHODS: Eighty-nine patients with bidimensionally measurable ACC previously untreated for metastatic disease were randomly allocated to receive oxaliplatin 130 mg/m(2) day 1 plus capecitabine 2,000 mg/m(2)/d days 1 to 14 every 3 weeks (arm A) or to receive oxaliplatin 85 mg/m(2) days 1 and 14 combined with capecitabine 3,500 mg/m(2) days 1 to 7 and 14 to 21 every 4 weeks (arm B). In both treatment arms, chemotherapy was continued for a total of 6 months unless there was prior evidence of progression of disease. RESULTS: Patients allocated to the high-dose capecitabine combination arm B had a higher radiologically confirmed response rate (54.5% v 42.2%) and a significantly longer median progression-free survival time than those allocated to control arm A (10.5 v 6.0 months; P =.0013). Median overall survival times cannot be calculated for either treatment arm at this point. Despite a 34% higher dose intensity of capecitabine in arm B, there was no difference in hematologic toxicity between treatment arms (neutropenia/thrombocytopenia: 60%/43% in arm B v 56%/33% in arm A). Similarly, the incidence rate and degree of nonhematologic adverse events were comparable: The most commonly encountered symptoms (all grades, arm A and arm B) included nausea/emesis (A: 58%; B: 62%), diarrhea (A: 44%; B: 31%), peripheral sensory neuropathy (A: 80%; B: 83%), and fatigue (A: 40%; B: 50%). CONCLUSION: Results of this study indicate that both combination regimens are feasible, tolerable, and clinically active. The dose-intensified bimonthly capecitabine arm, however, seems to be more effective in increasing both response rate and progression-free survival time.


Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Colorectal Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Deoxycytidine/administration & dosage , Organoplatinum Compounds/administration & dosage , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Capecitabine , Colorectal Neoplasms/mortality , Drug Administration Schedule , Female , Fluorouracil/analogs & derivatives , Follow-Up Studies , Humans , Male , Middle Aged , Oxaliplatin , Treatment Outcome
3.
Acta Med Austriaca ; 29(4): 124-31, 2002.
Article in German | MEDLINE | ID: mdl-12424937

ABSTRACT

AIM: To evaluate the efficacy of combined raltitrexed and oxaliplatin in vitro using 4 colorectal cell-lines and subsequently in vivo in 36 patients with advanced colorectal cancer failing palliative 5-fluorouracil/leucovorin-based chemotherapy. In the preclinical phase of this study, the efficacy of oxaliplatin and of raltitrexed as well as of 5-FU alone and in combination was evaluated in 4 different human colorectalcarcinoma cell-lines with the MTT-test (Microculture Tetrazolium Assay). In the clinical phase 36 patients with metastatic colorectal cancer, who progressed while receiving or within 6 months after withholding palliative chemotherapy with 5-FU/leucovorin +/- irinotecan were enrolled in this study. Treatment consisted of oxaliplatin 130 mg/m2 and raltitrexed 3.0 mg/m2 both given on day 1 every 3 weeks for a total of 8 courses unless prior evidence of progressive disease. A supraadditive effect was found for the experimental combination of oxalipatin and raltitrexed in 3/4 of cell lines. In the clinical phase the overall response rate was 33.3% for all 36 evaluable patients. Seventeen additional patients (47.2%) had stable disease, and only 7 (19.5%) progressed. The median progression-free survival was 6.5 months (range, 1.2 to 14.0). After a median follow-up time of 12 months, 23 patients (63.8%) are still alive. The tolerance of treatment was acceptable with only 8/36 (22%) experiencing grade 3 or 4 neutropenia. Grade 3 nonhematologic adverse reactions included peripheral sensory neuropathy in 3, asthenia in 1, diarrhea in 2, and clinically insignificant increase in serum transaminases in 2 patients, respectively. Our data suggest that the combination of oxaliplatin and raltitrexed has not only in vitro, but also in vivo in patients with progressive fluoropyrimidine/leucovorine +/- irinotecan pretreated colorectal cancer antitumor activity. Because of its favorable toxicity profile and its convenient 3-weekly outpatient administration schedule, further evaluation of this regimen seems warranted.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Colorectal Neoplasms/drug therapy , Organoplatinum Compounds/therapeutic use , Quinazolines/therapeutic use , Thiophenes/therapeutic use , Antineoplastic Agents/adverse effects , Antineoplastic Agents/toxicity , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/toxicity , Cell Survival/drug effects , Colorectal Neoplasms/pathology , Disease-Free Survival , Drug Synergism , Drug Therapy, Combination , Follow-Up Studies , Humans , Neoplasm Staging , Organoplatinum Compounds/adverse effects , Organoplatinum Compounds/toxicity , Oxaliplatin , Quinazolines/toxicity , Thiophenes/toxicity , Time Factors , Tumor Cells, Cultured
4.
Anticancer Drugs ; 13(5): 491-5, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12045460

ABSTRACT

A phase II study was performed to assess the safety and efficacy of mitoxantrone and cisplatin in locally recurrent and/or metastatic carcinomas of the salivary glands. Between May 1997 and March 2001, a total of 14 patients were entered on this trial. All of them had previously undergone radical resection and 10 were subsequently treated with adjuvant radiation therapy with (n=3) or without (n=7) concomitant chemotherapy. Therapy according to the study protocol consisted of mitoxantrone given as i.v. bolus on day 1 at a dose of 12 mg/m2 and cisplatin given as 90-min infusion at a dose of 30 mg/m2 on days 1-3. We observed two partial responses (14.3%) and stabilization of disease in nine patients (64.3%); progression during therapy was noted in only three cases (21.4%). The median time to progression was 15 months (range 2-36) and the median survival time was 27 months (range 4-54). Myelosuppression was commonly observed. Leukocytopenia occurred in all patients, and was grade 3 or 4 in three (21%) and four (29%) patients. WHO grade 3 thrombocytopenia and anemia was seen in three (21%) and four (29%) patients, respectively. Non-hematologic toxicity was in general mild to moderate except for two cases (14%) of grade 3 nausea and vomiting; overall incidence rates were nausea and vomiting (n=14), stomatitis (n=6), diarrhea (n=3), alopecia (n=11), infection (n=7), increase of serum creatinine (n=3), and peripheral neuropathy (n=3). The combination of mitoxantrone and cisplatin seems to be an active and fairly well-tolerated regimen for the treatment of advanced salivary gland cancers. According to the observed high rate of abrogating progressive disease for a long duration, and the resulting promising progression-free and overall survival time, further investigation seems warranted.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/drug therapy , Neoplasm Recurrence, Local/drug therapy , Salivary Gland Neoplasms/drug therapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Chemotherapy, Adjuvant , Cisplatin/administration & dosage , Disease-Free Survival , Drug Administration Schedule , Humans , Lung Neoplasms/secondary , Middle Aged , Mitoxantrone/administration & dosage , Nausea/chemically induced , Neoplasm Recurrence, Local/pathology , Neutropenia/chemically induced , Palliative Care , Salivary Gland Neoplasms/pathology , Survival Rate , Treatment Outcome
5.
Clin Cancer Res ; 8(5): 1051-6, 2002 May.
Article in English | MEDLINE | ID: mdl-12006518

ABSTRACT

PURPOSE: A multicenter Phase II trial was performed to investigate the efficacy and tolerance of combined docetaxel and gemcitabine +/- recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with metastatic breast cancer. PATIENTS AND METHODS: Fifty-two patients participated in this trial, 51 of whom are evaluable for response. Thirty-eight patients received this combination as first-line chemotherapy, and 14 patients received this combination as second-line chemotherapy, including 10 patients who had failed anthracyclines. Therapy consisted of 1500 mg/m2 gemcitabine and 50 mg/m2 docetaxel, both administered on days 1 and 15 every 4 weeks. Depending on the absolute neutrophil counts on the day of scheduled chemotherapeutic drug administration, a 5-day course of 5 microg/kg G-CSF was given. RESULTS: The overall response rate was 60.5% (95% confidence interval, 43.4-75.9%) in patients receiving docetaxel plus gemcitabine as first-line chemotherapy, including 4 complete responses (10.5%) and 19 partial remissions (50%); 9 patients (24%) had disease stabilization, and only 5 (13%) progressed. Second-line treatment with this regimen resulted in 6 of 14 (43%) objective responses, 5 had stable disease, and 3 progressive disease. The median time to progression was 8.5 months in the first-line setting and 6.6 months in the second-line setting, respectively. After a median follow-up time of 15 months, 36 patients (69%) are still alive with metastatic disease. Myelosuppression was commonly observed; WHO grade 3 or 4 neutropenia, however, occurred in only 15 (29%) patients and was complicated by septicemia in 2 cases; grade 3 anemia was seen in 1 patient (2%). Severe (grade 3) nonhematological toxicity except for alopecia was rarely observed and included nausea/vomiting in 3 (6%), stomatitis in 2 (4%), anaphylaxis in 2, and peripheral neuropathy, skin toxicity, and increase of liver enzymes each in one patient. CONCLUSION: Our data suggest that docetaxel and gemcitabine with and without G-CSF is an effective and fairly well-tolerated regimen for the treatment of advanced breast cancer. It might be particularly useful in patients exposed previously to adjuvant or palliative anthracyclines and/or alkylating agents.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Deoxycytidine/analogs & derivatives , Paclitaxel/analogs & derivatives , Taxoids , Adult , Aged , Anemia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Breast Neoplasms/pathology , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Docetaxel , Fatigue/chemically induced , Female , Granulocyte Colony-Stimulating Factor/administration & dosage , Granulocyte Colony-Stimulating Factor/adverse effects , Humans , Leukopenia/chemically induced , Middle Aged , Nausea/chemically induced , Nervous System Diseases/chemically induced , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Survival Analysis , Treatment Outcome , Gemcitabine
6.
J Clin Oncol ; 20(1): 165-72, 2002 Jan 01.
Article in English | MEDLINE | ID: mdl-11773166

ABSTRACT

PURPOSE: Irinotecan and oxaliplatin are two new agents with promising activity in advanced colorectal cancer. Based on preclinical and clinical evidence that both drugs act synergistically, a randomized phase II study was initiated to investigate the therapeutic potential and tolerance of this combination in the front-line setting. PATIENTS AND METHODS: Ninety-two patients with previously untreated, measurable disease were randomized to receive biweekly oxaliplatin 85 mg/m(2) plus irinotecan 175 mg/m(2) or raltitrexed 3 mg/m(2) given on day 1 every 3 weeks. Upon development of progressive disease, second-line treatment with the opposite arm was effected. RESULTS: Patients allocated to oxaliplatin/irinotecan had a significantly better radiologically confirmed response rate (43.5% v 19.6%; P =.0025) and longer progression-free survival (median, 7.1 v 5.0 months; P =.0033). Improvement in overall survival, however, did not reach the level of significance (median, 16.0 v 16.5 months; P =.3943). The response rate after cross-over was 33.3% (eight of 24) for assessable patients treated with oxaliplatin/irinotecan compared with 14.2% (three of 21) for those treated with second-line raltitrexed. Oxaliplatin/irinotecan caused more hematologic and gastrointestinal toxicities, necessitating dose reductions in 10 of the first 20 patients. After adjustment of the irinotecan starting dose from 175 to 150 mg/m(2), tolerance of treatment was acceptable; the most commonly encountered events (all grades) were neutropenia (81%), alopecia (65%), nausea/emesis (62%), peripheral sensory neuropathy (62%), and diarrhea (46%). CONCLUSION: Oxaliplatin/irinotecan seems beneficial as first-line therapy in advanced colorectal cancer, with an acceptable toxicity profile at the reduced irinotecan dose level. Its promising therapeutic potential is supported by the high response activity noted in the raltitrexed control arm after cross-over, which may also explain the lack of a difference in overall survival.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Camptothecin/analogs & derivatives , Colorectal Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adult , Aged , Antimetabolites, Antineoplastic/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Camptothecin/administration & dosage , Colorectal Neoplasms/mortality , Cross-Over Studies , Disease-Free Survival , Dose-Response Relationship, Drug , Drug Synergism , Female , Humans , Irinotecan , Male , Middle Aged , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Palliative Care , Quinazolines/therapeutic use , Survival Rate , Thiophenes/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...